Dexamethasone intravitreous implant <i>versus</i> bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison

Gado, Ahmed; Macky, Tamer A.

doi:10.1111/ceo.12311

Cited by 47 publications

(31 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, more anti-VEGF injections according to IDI injections are required to maintain similar clinical activity after the 3 rd month. [ 19 20 ]…”

Section: Discussionmentioning

confidence: 99%

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

Şimşek

Çıtırık

Özateş

et al. 2018

Indian J Ophthalmol

View full text Add to dashboard Cite

Purpose:This study evaluated the effect of intravitreal dexamethasone implant (IDI; Ozurdex) injection for treating macular edema in patients with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).Methods:This prospective study included 40 eyes of 40 patients with nonischemic BRVO and 31 eyes of 31 patients with nonischemic CRVO who received IDI injection as the first-line treatment for macular edema. The best-corrected visual acuity (BCVA) value before and after the treatment; intraocular pressure; optic coherence tomography findings; and all ocular examination findings, including central foveal thickness (CFT) measurement and fluorescein angiography findings, were evaluated for each patient.Results:After the IDI injection, BCVA value increased (P < 0.001) and CFT value decreased (P < 0.001) in both groups. The recurrence rates of CFT elevation after the first and the second Ozurdex injections were 65.0% and 65.3%, respectively, in patients with BRVO and 70.9% and 68.1%, respectively, in patients with CRVO. A statistically significant correlation was observed between preinjection CFT value and postinjection recurrence of CFT elevation (P = 0.017).Conclusion:Treatment with the IDI injections resulted in significant short-term improvement in CFT and BCVA values in patients with clinically significant RVO-related macular edema. Moreover, we observed that high preinjection CFT value was associated with a risk of postinjection recurrence of CFT elevation.

show abstract

“…Therefore, more anti-VEGF injections according to IDI injections are required to maintain similar clinical activity after the 3 rd month. [ 19 20 ]…”

Section: Discussionmentioning

confidence: 99%

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

Şimşek

Çıtırık

Özateş

et al. 2018

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Therefore, anti-VEGF agents are the preferred treatment in these cases. [ 141 142 143 144 145 146 147 148 ] EL: I…”

Section: Resultsmentioning

confidence: 99%

Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline

Nikkhah¹,

Karimi²,

Ahmadieh³

et al. 2018

J Ophthalmic Vis Res

View full text Add to dashboard Cite

Purpose:To provide the clinical recommendations for the administration of intravitreal anti-vascular endothelial growth factor (VEGF) drugs especially bavacizumab for ocular vascular diseases including diabetic macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, retinal vein occlusion and central serous chorioretinopathy.Methods:Twenty clinical questions were developed by the guideline technical committee. Relevant websites and databases were searched to find out the pertinent clinical practice guidelines to answer the questions. The technical committee provided possible answers (scenarios) according to the available evidences for each question. All scenarios along with their levels of evidence and the supported articles were sent to the experts for external review. If the experts did not agree on any of the scenarios for one particular clinical question, the technical committee reviewed all scenarios and their pertinent evidences and made the necessary decision. After that, the experts were asked to score them again. All confirmed scenarios were gathered as the final recommendations.Results:All the experts agreed on at least one of the scenarios. The technical committee extracted the agreed scenario for each clinical question as the final recommendation. Finally, 56 recommendations were developed for the procedure of intravitreal anti-VEGF injection and their applications in the management of ocular vascular diseases.Conclusion:The implementation of this guideline can standardize the management of the common ocular vascular diseases by intravitreal injection of anti-VEGF agents. It can lead to better policy-making and evidence-based clinical decision by ophthalmologists and optimal evidence based eye care for patients.

show abstract

“…İVD implant grubunda, görme keskinliğinde 15 harf artış olan hasta sayısı ve OKT'de MÖ'de azalma "Sham grubu"na göre anlamlı olarak bulunmuştur. 19,24,34,35 Bizim çalışmamızda,15 harf ve daha üzeri görme keskinliği artışı olan göz sayısı en fazla 60. günde tespit edildi (%27) ve bu etki azalarak 180. günde %18 seviyesine geriledi.…”

Section: Discussionunclassified

Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Central Retinal Vein Occlusion: Six Months Results

Şengül¹,

Artunay²,

Kumral³

et al. 2016

Turkiye Klinikleri J Ophthalmol

View full text Add to dashboard Cite

30antral retinal ven tıkanıklığı (SRVT), retina ven dal tıkanıklığından (RVDT)'dan daha az görülmesine rağmen, görme keskinliğinde azalma yapan ve sık görülen bir retina damarsal hastalığıdır. A An na ah ht ta ar r K Ke el li im me el le er r: : İntravitreal enjeksiyon; makula ödemi; retinal ven tıkanıklığı A AB BS ST TR RA AC CT T O Ob bj je ec ct ti iv ve e: : To determine six-month results after a single application of dexamethasone intravitreal implant used in macular edema following central retinal vein occlusion (CRVO). M Ma a--t te er ri ia al l a an nd d M Me et th ho od ds s: : The findings of 22 eyes of 22 patients diagnosed (ME) macusluar edema following control retinal vein occlusion CRVO were evaluated retrospectively. Patients were examined in 1, 7, 30, 90 and 180 days after injection. The best visual acuity of patients was measured by Snellen chart at each visit, and the results were converted to ETDRS letters scoring. Biomicroscopy, tonometry, fundoscopy and optic coherence tomography (OCT) were made in every visit. R Re es su ul lt ts s: : Visual acuity increase was 1.1±1.5, 2.9±1.8, 8.5±1.9, 9.8±4.7, 8.0±1.8, 4.0±1.3 letters in 1 st , 7 th , 30 th , 60 th , 90 th and 180 th day respectively. The maximum response of the patients visual acuity was observed in the second month and visual acuity increase began to decline from the third month. The reduction in macular thickness in patients was 14±7.8, 71±12.8, 132±11.4, 205±5.4, 140±6.6, 120±7.6 μm in day 1, 7, 30, 60, 90 and 180 respectively. Macular thickness showed an increase trend after third months. C Co on nc cl lu us si io on n: : Clinically significant improvement in visual acuity and macular thickness reduction is provided with single application of dexamethasono intravitreal implant IVD. This positive effect reached the maximum level in third months and started to decrease by sixth months.

show abstract

Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison

Abstract: Both drugs provided effective best corrected visual acuity improvements and central subfield thickness reductions that showed no statistically significant difference between the two groups.

Cited by 47 publications

References 14 publications

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline

Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Central Retinal Vein Occlusion: Six Months Results

Contact Info

Product

Resources

About